{"id":"https://openalex.org/W1799052194","doi":"https://doi.org/10.1212/wnl.82.10_supplement.p1.186","title":"Blocking LINGO-1 Does Not Affect Inflammatory Markers in the Cerebrospinal Fluid of Individuals with Multiple Sclerosis (P1.186)","display_name":"Blocking LINGO-1 Does Not Affect Inflammatory Markers in the Cerebrospinal Fluid of Individuals with Multiple Sclerosis (P1.186)","publication_year":2014,"publication_date":"2014-04-08","ids":{"openalex":"https://openalex.org/W1799052194","doi":"https://doi.org/10.1212/wnl.82.10_supplement.p1.186","mag":"1799052194"},"language":"en","primary_location":{"id":"doi:10.1212/wnl.82.10_supplement.p1.186","doi":"https://doi.org/10.1212/wnl.82.10_supplement.p1.186","is_oa":false,"landing_page_url":"https://doi.org/10.1212/wnl.82.10_supplement.p1.186","pdf_url":null,"source":{"id":"https://openalex.org/S79704628","display_name":"Neurology","issn_l":"0028-3878","issn":["0028-3878","1526-632X"],"is_oa":false,"is_in_doaj":false,"is_core":true,"listed_in":["anvur-scientific","cwts-core","dongbi-a","doyens","jufo-3","ki-jl-2","medline","norway-2","poland-140","russia-white-list-1","vabb-shw"],"host_organization":"https://openalex.org/P4310315671","host_organization_name":"Lippincott Williams & Wilkins","host_organization_lineage":["https://openalex.org/P4310315671","https://openalex.org/P4310318547"],"host_organization_lineage_names":["Lippincott Williams & Wilkins","Wolters Kluwer"],"type":"journal"},"license":null,"license_id":null,"version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"Neurology","raw_type":"journal-article"},"volume":null,"type":"article","indexed_in":["crossref"],"open_access":{"is_oa":false,"oa_status":"closed","oa_url":null,"any_repository_has_fulltext":false},"authorships":[{"author_position":"first","author":{"id":"https://openalex.org/A5027421276","display_name":"Ann M. Ranger","orcid":null,"observed_orcids":[]},"institutions":[{"id":"https://openalex.org/I1297540436","display_name":"Biogen (United States)","ror":"https://ror.org/02jqkb192","country_code":"US","type":"company","lineage":["https://openalex.org/I1297540436"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Ann Ranger","raw_affiliation_strings":["Biogen Idec Cambridge MA United States","1Biogen Idec Cambridge MA United States"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Biogen Idec Cambridge MA United States","institution_ids":["https://openalex.org/I1297540436"]},{"raw_affiliation_string":"1Biogen Idec Cambridge MA United States","institution_ids":["https://openalex.org/I1297540436"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5014834868","display_name":"Soma S. Ray","orcid":"https://orcid.org/0009-0006-9482-0203","observed_orcids":["https://orcid.org/0009-0006-9482-0203"]},"institutions":[{"id":"https://openalex.org/I1297540436","display_name":"Biogen (United States)","ror":"https://ror.org/02jqkb192","country_code":"US","type":"company","lineage":["https://openalex.org/I1297540436"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Soma Ray","raw_affiliation_strings":["Biogen Idec Cambridge MA United States","1Biogen Idec Cambridge MA United States"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Biogen Idec Cambridge MA United States","institution_ids":["https://openalex.org/I1297540436"]},{"raw_affiliation_string":"1Biogen Idec Cambridge MA United States","institution_ids":["https://openalex.org/I1297540436"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5010626323","display_name":"Suzanne T. Szak","orcid":null,"observed_orcids":[]},"institutions":[{"id":"https://openalex.org/I1297540436","display_name":"Biogen (United States)","ror":"https://ror.org/02jqkb192","country_code":"US","type":"company","lineage":["https://openalex.org/I1297540436"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Suzanne Szak","raw_affiliation_strings":["Biogen Idec Cambridge MA United States","1Biogen Idec Cambridge MA United States"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Biogen Idec Cambridge MA United States","institution_ids":["https://openalex.org/I1297540436"]},{"raw_affiliation_string":"1Biogen Idec Cambridge MA United States","institution_ids":["https://openalex.org/I1297540436"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5026099131","display_name":"Andrea T. Dearth","orcid":null,"observed_orcids":[]},"institutions":[{"id":"https://openalex.org/I1297540436","display_name":"Biogen (United States)","ror":"https://ror.org/02jqkb192","country_code":"US","type":"company","lineage":["https://openalex.org/I1297540436"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Andrea Dearth","raw_affiliation_strings":["Biogen Idec Cambridge MA United States","1Biogen Idec Cambridge MA United States"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Biogen Idec Cambridge MA United States","institution_ids":["https://openalex.org/I1297540436"]},{"raw_affiliation_string":"1Biogen Idec Cambridge MA United States","institution_ids":["https://openalex.org/I1297540436"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5006344036","display_name":"Norm Allaire","orcid":"https://orcid.org/0000-0002-3497-8459","observed_orcids":["https://orcid.org/0000-0002-3497-8459"]},"institutions":[{"id":"https://openalex.org/I1297540436","display_name":"Biogen (United States)","ror":"https://ror.org/02jqkb192","country_code":"US","type":"company","lineage":["https://openalex.org/I1297540436"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Normand Allaire","raw_affiliation_strings":["Biogen Idec Cambridge MA United States","1Biogen Idec Cambridge MA United States"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Biogen Idec Cambridge MA United States","institution_ids":["https://openalex.org/I1297540436"]},{"raw_affiliation_string":"1Biogen Idec Cambridge MA United States","institution_ids":["https://openalex.org/I1297540436"]}]},{"author_position":"last","author":{"id":"https://openalex.org/A5088163706","display_name":"Diego Cadavid","orcid":"https://orcid.org/0000-0002-5361-3834","observed_orcids":["https://orcid.org/0000-0002-5361-3834"]},"institutions":[{"id":"https://openalex.org/I1297540436","display_name":"Biogen (United States)","ror":"https://ror.org/02jqkb192","country_code":"US","type":"company","lineage":["https://openalex.org/I1297540436"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Diego Cadavid","raw_affiliation_strings":["Biogen Idec Cambridge MA United States","1Biogen Idec Cambridge MA United States"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Biogen Idec Cambridge MA United States","institution_ids":["https://openalex.org/I1297540436"]},{"raw_affiliation_string":"1Biogen Idec Cambridge MA United States","institution_ids":["https://openalex.org/I1297540436"]}]}],"institutions":[],"countries_distinct_count":1,"institutions_distinct_count":1,"corresponding_author_ids":[],"corresponding_institution_ids":["https://openalex.org/I1297540436"],"apc_list":null,"apc_paid":null,"fwci":0.0,"has_fulltext":false,"cited_by_count":1,"citation_normalized_percentile":{"value":0.08035489,"is_in_top_1_percent":false,"is_in_top_10_percent":false},"cited_by_percentile_year":{"min":89,"max":94},"biblio":{"volume":"82","issue":"10_supplement","first_page":null,"last_page":null},"is_retracted":false,"is_paratext":false,"is_xpac":false,"primary_topic":{"id":"https://openalex.org/T10137","display_name":"Multiple Sclerosis Research Studies","score":1.0,"subfield":{"id":"https://openalex.org/subfields/2734","display_name":"Pathology and Forensic Medicine"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}},"topics":[{"id":"https://openalex.org/T10137","display_name":"Multiple Sclerosis Research Studies","score":1.0,"subfield":{"id":"https://openalex.org/subfields/2734","display_name":"Pathology and Forensic Medicine"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}},{"id":"https://openalex.org/T10469","display_name":"Psoriasis: Treatment and Pathogenesis","score":0.0,"subfield":{"id":"https://openalex.org/subfields/2403","display_name":"Immunology"},"field":{"id":"https://openalex.org/fields/24","display_name":"Immunology and Microbiology"},"domain":{"id":"https://openalex.org/domains/1","display_name":"Life Sciences"}},{"id":"https://openalex.org/T11266","display_name":"Neuroinflammation and Neurodegeneration Mechanisms","score":0.0,"subfield":{"id":"https://openalex.org/subfields/2808","display_name":"Neurology"},"field":{"id":"https://openalex.org/fields/28","display_name":"Neuroscience"},"domain":{"id":"https://openalex.org/domains/1","display_name":"Life Sciences"}}],"keywords":[{"id":"https://openalex.org/keywords/lingo-1","display_name":"LINGO-1","score":0.9959999918937683},{"id":"https://openalex.org/keywords/multiple-sclerosis","display_name":"multiple sclerosis","score":0.9390000104904175},{"id":"https://openalex.org/keywords/relapsing-remitting-multiple-sclerosis","display_name":"relapsing-remitting multiple sclerosis","score":0.949999988079071},{"id":"https://openalex.org/keywords/secondary-progressive-multiple-sclerosis","display_name":"secondary progressive multiple sclerosis","score":0.9959999918937683},{"id":"https://openalex.org/keywords/cerebrospinal-fluid","display_name":"cerebrospinal fluid","score":0.7730000019073486},{"id":"https://openalex.org/keywords/inflammation","display_name":"inflammation","score":0.4749999940395355},{"id":"https://openalex.org/keywords/remyelination","display_name":"remyelination","score":0.8970000147819519},{"id":"https://openalex.org/keywords/monoclonal-antibodies","display_name":"monoclonal antibodies","score":0.8309999704360962},{"id":"https://openalex.org/keywords/cytokines","display_name":"cytokines","score":0.6510000228881836},{"id":"https://openalex.org/keywords/chemokines","display_name":"chemokines","score":0.9120000004768372},{"id":"https://openalex.org/keywords/antibody-isotypes","display_name":"antibody isotypes","score":0.8669999837875366}],"concepts":[{"id":"https://openalex.org/C2780640218","wikidata":"https://www.wikidata.org/wiki/Q8277","display_name":"Multiple sclerosis","level":2,"score":0.8244041204452515},{"id":"https://openalex.org/C2779651940","wikidata":"https://www.wikidata.org/wiki/Q54196","display_name":"Cerebrospinal fluid","level":2,"score":0.7306119203567505},{"id":"https://openalex.org/C2776035688","wikidata":"https://www.wikidata.org/wiki/Q1606558","display_name":"Affect (linguistics)","level":2,"score":0.5849562287330627},{"id":"https://openalex.org/C71924100","wikidata":"https://www.wikidata.org/wiki/Q11190","display_name":"Medicine","level":0,"score":0.5067773461341858},{"id":"https://openalex.org/C142724271","wikidata":"https://www.wikidata.org/wiki/Q7208","display_name":"Pathology","level":1,"score":0.360114723443985},{"id":"https://openalex.org/C15744967","wikidata":"https://www.wikidata.org/wiki/Q9418","display_name":"Psychology","level":0,"score":0.32168325781822205},{"id":"https://openalex.org/C203014093","wikidata":"https://www.wikidata.org/wiki/Q101929","display_name":"Immunology","level":1,"score":0.298292338848114},{"id":"https://openalex.org/C46312422","wikidata":"https://www.wikidata.org/wiki/Q11024","display_name":"Communication","level":1,"score":0.09301644563674927}],"mesh":[],"locations_count":1,"locations":[{"id":"doi:10.1212/wnl.82.10_supplement.p1.186","doi":"https://doi.org/10.1212/wnl.82.10_supplement.p1.186","is_oa":false,"landing_page_url":"https://doi.org/10.1212/wnl.82.10_supplement.p1.186","pdf_url":null,"source":{"id":"https://openalex.org/S79704628","display_name":"Neurology","issn_l":"0028-3878","issn":["0028-3878","1526-632X"],"is_oa":false,"is_in_doaj":false,"is_core":true,"listed_in":["anvur-scientific","cwts-core","dongbi-a","doyens","jufo-3","ki-jl-2","medline","norway-2","poland-140","russia-white-list-1","vabb-shw"],"host_organization":"https://openalex.org/P4310315671","host_organization_name":"Lippincott Williams & Wilkins","host_organization_lineage":["https://openalex.org/P4310315671","https://openalex.org/P4310318547"],"host_organization_lineage_names":["Lippincott Williams & Wilkins","Wolters Kluwer"],"type":"journal"},"license":null,"license_id":null,"version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"Neurology","raw_type":"journal-article"}],"best_oa_location":null,"sustainable_development_goals":[{"score":0.9537000060081482,"id":"https://metadata.un.org/sdg/3","display_name":"Good health and well-being"}],"sustainable_development_goals_aurora":[{"score":0.7699999809265137,"id":"https://metadata.un.org/sdg/3","display_name":"Good health and well-being"}],"study_designs":[],"awards":[],"funders":[],"has_content":{"grobid_xml":false,"pdf":false},"content_urls":null,"referenced_works_count":0,"referenced_works":[],"related_works":["https://openalex.org/W1859950650","https://openalex.org/W1992419170","https://openalex.org/W1480919427","https://openalex.org/W2314725075","https://openalex.org/W1996248347","https://openalex.org/W2528072478","https://openalex.org/W2752401912","https://openalex.org/W2131261210","https://openalex.org/W2324349338","https://openalex.org/W7045761447"],"abstract_inverted_index":{"OBJECTIVE:":[0],"To":[1],"evaluate":[2,177],"whether":[3],"blocking":[4,54],"LINGO-1":[5,19,55,93,268],"in":[6,14,43,58,79,95,107,205,208,221,241,244,262],"individuals":[7],"with":[8,62,100,229,250,267],"MS":[9,51,266],"is":[10,31,255],"accompanied":[11],"by":[12,159],"changes":[13,204,240],"intrathecal":[15],"inflammatory":[16,242],"signals.":[17],"BACKGROUND:":[18],"(leucine-rich":[20],"repeats":[21],"and":[22,77,84,103,122,130,138,155,163,184,195,252],"immunoglobulin":[23],"[Ig]":[24],"domain-containing":[25],"neurite":[26],"outgrowth":[27],"inhibitor":[28],"receptor-interacting":[29],"protein-1)":[30],"a":[32,69,80,171,231],"component":[33],"of":[34,50,89,92,114,146,180,187,214,247,265],"CNS":[35],"signaling":[36],"complexes":[37],"that":[38,53],"suppress":[39],"remyelination.":[40],"Preclinical":[41],"studies":[42],"the":[44,86,90,108,143,188,209,245],"rodent":[45],"experimental":[46],"autoimmune":[47],"encephalomyelitis":[48],"model":[49],"show":[52],"improves":[56],"remyelination":[57],"spinal":[59],"cord":[60],"axons":[61],"no":[63,238],"concomitant":[64],"effect":[65],"on":[66,127],"inflammation.":[67],"BIIB033,":[68,230],"fully":[70],"humanized":[71],"monoclonal":[72,232],"antibody,":[73],"has":[74,259],"been":[75,260],"developed":[76,175],"tested":[78],"phase":[81],"I":[82],"trial":[83],"affords":[85],"first":[87],"view":[88],"impact":[91],"blockade":[94],"humans.":[96],"METHODS:":[97],"Twenty":[98],"participants":[99,249],"RRMS":[101,251],"(n=15)":[102],"SPMS":[104],"(n=5)":[105],"enrolled":[106],"Phase":[109],"1,":[110],"multiple,":[111],"ascending-dose":[112],"study":[113,248],"BIIB033":[115,224],"were":[116,134,157,237],"randomized":[117],"to":[118,176,223,234,257],"receive":[119],"30,":[120],"60":[121],"100":[123],"mg/kg":[124],"or":[125,218],"placebo":[126],"days":[128],"0":[129],"14.":[131],"Lumbar":[132],"punctures":[133],"performed":[135],"before":[136],"dosing":[137],"repeated":[139],"2":[140],"weeks":[141],"after":[142],"final":[144],"dose":[145],"BIIB033.":[147],"RNA":[148],"was":[149,174],"isolated":[150],"from":[151],"pelleted":[152],"CSF":[153,210,246],"cells":[154],"transcripts":[156,178,207],"analyzed":[158],"global":[160],"microarray":[161],"(Affymetrix)":[162],"quantitative":[164],"polymerase":[165],"chain":[166],"reaction":[167],"(qPCR).":[168],"For":[169],"qPCR,":[170],"custom":[172],"panel":[173],"representative":[179],"specific":[181],"cell":[182,211,216],"types":[183,217],"soluble":[185,219],"proteins":[186],"immune":[189,215],"system,":[190],"including":[191],"Immunoglobulin":[192],"isotypes,":[193],"cytokines":[194],"chemokines.":[196],"RESULTS:":[197],"We":[198],"did":[199],"not":[200],"observe":[201],"any":[202],"consistent":[203],"mRNA":[206],"pellet":[212],"indicative":[213],"effectors":[220],"response":[222],"administration.":[225],"CONCLUSIONS:":[226],"After":[227],"treatment":[228],"antibody":[233],"LINGO-1,":[235],"there":[236],"significant":[239],"markers":[243],"SPMS.":[253],"This":[254],"similar":[256],"what":[258],"observed":[261],"preclinical":[263],"models":[264],"blockade.":[269],"Study":[270],"Supported":[271],"by:":[272],"Biogen":[273],"Idec":[274]},"counts_by_year":[{"year":2018,"cited_by_count":1}],"updated_date":"2026-09-29T14:09:16.559479","created_date":"2016-06-24T00:00:00"}